Vertex Pharmaceuticals (VRTX) has entered into a three-year research collaboration with Orna Therapeutics to develop gene editing therapies for sickle cell disease and transfusion-dependent beta thalassemia, Orna said Tuesday.
The collaboration will use Orna's lipid nanoparticle delivery system to advance Vertex's therapeutic development, Orna said.
Under the agreement, Orna said it will receive $65 million upfront, including a convertible note investment, and could earn up to $635 million based on achieving milestones for SCD/TDT products.
Orna said it is eligible for up to $365 million in additional option fees and milestones per product for up to 10 additional products if Vertex exercises rights for new indications, and will also receive tiered royalties on future sales. Vertex is financing the research collaboration and has the option to extend its duration.
Shares of Vertex were up 1.9% in recent Tuesday trading.
Price: 409.97, Change: +7.48, Percent Change: +1.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。